https://m2.mtmt.hu/ hun 2026-09-21 18:30 JournalArticle 35663377 VALIDATED true Funding Agency and Grant Number: Ministry of Innovation and Technology of Hungary [TKP2021-EGA-23, TKP2021-EGA-25]; Ministry of Innovation and Technology of Hungary from the National Research, Development, and Innovation Fund [OTKA-K128875, NKFI K 146086]; National Research, Development, and Innovation Office of Hungary Funding text: This work was supported by the Ministry of Innovation and Technology of Hungary from the National Research, Development, and Innovation Fund, financed under the TKP2021-EGA-23 and TKP2021-EGA-25 funding schemes by the research fund of the National Research, Development, and Innovation Office of Hungary (OTKA-K128875 to T.Z. and NKFI K 146086 to Z.E.T.). 0 false 2026-09-08T08:46:52.744+0000 2026-04-29T06:04:11.530+0000 2025-01-06T10:08:28.993+0000 true 10015484 Al-Khrasani Mahmoud /api/author/10015484 Author Al-Khrasani Mahmoud (Farmakológia) true 10015484 2026-09-07T07:41:41.802+0000 2026-09-07T07:41:41.802+0000 2025-05-25T16:34:16.434+0000 true 10026589 Tichy Rita /api/admin/10026589 Admin Tichy Rita (SE_KK_Admin5_TR, admin) true 10026589 Admin 10025544 /api/admin/10025544 Lévayné Deseő Katalin (MTMT Központi admin) Lévayné Deseő Katalin true 10025544 true 2026-05-20T07:50:04.154+0000 true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 10000059 Article true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/10000059 Szakcikk SubType Szakcikk (Folyóiratcikk) 101 true 10000059 true 1 /api/category/1 Category Tudományos true 1 Papp, Zsolt Tamás true true /api/journal/10056704 REVIEWED BIOMEDICINES 2227-9059 true false 10056704 false 10056704 true 2227-9059 Journal FOREIGN 13 1 71 71 19 2025 Background: N-methyl-D-aspartate type glutamate receptors (NMDARs) are fundamental to neuronal physiology and pathophysiology. The prefrontal cortex (PFC), a key region for cognitive function, is heavily implicated in neuropsychiatric disorders, positioning the modulation of its glutamatergic neurotransmission as a promising therapeutic target. Our recently published findings indicate that AT1 receptor activation enhances NMDAR activity in layer V pyramidal neurons of the rat PFC. At the same time, it suggests that alternative angiotensin pathways, presumably involving AT4 receptors (AT4Rs), might exert inhibitory effects. Angiotensin IV (Ang IV) and its analogs have demonstrated cognitive benefits in animal models of learning and memory deficits. Methods: Immunohistochemistry and whole-cell patch-clamp techniques were used to map the cell-type-specific localization of AT4R, identical to insulin-regulated aminopeptidase (IRAP), and to investigate the modulatory effects of Ang IV on NMDAR function in layer V pyramidal cells of the rat PFC. Results: AT4R/IRAP expression was detected in pyramidal cells and GABAergic interneurons, but not in microglia or astrocytes, in layer V of the PFC in 9–12-day-old and 6-month-old rats. NMDA (30 μM) induced stable inward cation currents, significantly inhibited by Ang IV (1 nM–1 µM) in a subset of pyramidal neurons. This inhibition was reproduced by the IRAP inhibitor LVVYP-H7 (10–100 nM). Synaptic isolation of pyramidal neurons did not affect the Ang IV-mediated inhibition of NMDA currents. Conclusions: Ang IV/IRAP-mediated inhibition of NMDA currents in layer V pyramidal neurons of the PFC may represent a way of regulating cognitive functions and thus a potential pharmacological target for cognitive impairments and related neuropsychiatric disorders. Funding 2049149 /api/funding/2049149 (OTKA-K128875) false true Funding 2049150 /api/funding/2049150 (NKFI K 146086) false true Funding 2049423 /api/funding/2049423 (TKP2021-EGA-23) Támogató: Innovációs és Technológiai Minisztérium false true Funding 2049424 /api/funding/2049424 (TKP2021-EGA-25) false true true true 2025 true true true false true false GOLD 2026-09-08 true https://real.mtak.hu/214751 5 0 4 4 0 4 4 4 4 4 4 4 4 5 0 0 5 5 4 4 0 11 11 Folyóiratcikk Journal Article 24 4 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 1 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2025 0 4 4 4 4 2026 0 1 1 1 1 Q1 false 10015484 false false false 2025-01-25T17:04:56.568+0000 Anatómiai, Szövet- és Fejlődéstani Intézet (SE / AOK / I); Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); Molekuláris Farmakológia Kutatócsoport (HRN KOKI); Orálbiológiai Tanszék (SE / FOK) 12 42 4 12 0 true 10025544 Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 122576245 /api/authorship/122576245 Papp, Zsolt Tamás [Papp, Zsolt Tamás (Farmakológia), szerző] Orálbiológiai Tanszék (SE / FOK); Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I) 1 0.083 true false false Author 10061052 /api/author/10061052 Papp Zsolt Tamás (Farmakológia) Papp Zsolt Tamás true 10061052 true Papp Zsolt Tamás true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 122576246 /api/authorship/122576246 Ribiczey, Polett [Szentirmainé Ribiczey, Polett (Farmakológia), szerző] Orálbiológiai Tanszék (SE / FOK); Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I) 2 0.083 false false false Author 10069236 /api/author/10069236 Szentirmainé Ribiczey Polett (Farmakológia) Szentirmainé Ribiczey Polett true true Ribiczey Polett true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 122576247 /api/authorship/122576247 Kató, Erzsébet [Kató, Erzsébet (Farmakológia), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I) 3 0.083 false false false Author 10015479 /api/author/10015479 Kató Erzsébet (Farmakológia) Kató Erzsébet true 10015479 true Kató Erzsébet true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 122576248 /api/authorship/122576248 Tóth, Zsuzsanna E. [Tóth, Zsuzsanna (Neuromorfológia, ...), szerző] Anatómiai, Szövet- és Fejlődéstani Intézet (SE / AOK / I) 4 0.083 false false false Author 10001325 /api/author/10001325 Tóth Zsuzsanna (Neuromorfológia, neuroendokrinológia) Tóth Zsuzsanna true 10001325 true Tóth Zsuzsanna E. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 122576249 /api/authorship/122576249 Varga, Zoltán V. [Varga, Zoltán (kardiovaszkuláris...), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I) 5 0.083 false false false Author 10028393 /api/author/10028393 Varga Zoltán (kardiovaszkuláris kutatás) Varga Zoltán true 10028393 true Varga Zoltán V. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 122576250 /api/authorship/122576250 Giricz, Zoltán [Giricz, Zoltán (Biokémia, Farmako...), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I) 6 0.083 false false false Author 10026898 /api/author/10026898 Giricz Zoltán (Biokémia, Farmakológia) Giricz Zoltán true 10026898 true Giricz Zoltán true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 122576251 /api/authorship/122576251 Hanuska, Adrienn [Hanuska, Adrienn (farmakológia), szerző] Orálbiológiai Tanszék (SE / FOK); Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I) 7 0.083 false false false Author 10039322 /api/author/10039322 Hanuska Adrienn (farmakológia) Hanuska Adrienn true 10039322 true Hanuska Adrienn true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 122576252 /api/authorship/122576252 Al-Khrasani, Mahmoud [Al-Khrasani, Mahmoud (Farmakológia), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I) 8 0.083 false false false Author 10015484 /api/author/10015484 Al-Khrasani Mahmoud (Farmakológia) Al-Khrasani Mahmoud true 10015484 true Al-Khrasani Mahmoud true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 122576253 /api/authorship/122576253 Zsembery, Ákos [Zsembery, Ákos (Élettan), szerző] Orálbiológiai Tanszék (SE / FOK) 9 0.083 false false false Author 10015697 /api/author/10015697 Zsembery Ákos (Élettan) Zsembery Ákos true 10015697 true Zsembery Ákos true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 122576254 /api/authorship/122576254 Zelles, Tibor [Zelles, Tibor (Idegtudományok), szerző] Molekuláris Farmakológia Kutatócsoport (HRN KOKI); Orálbiológiai Tanszék (SE / FOK); Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I) 10 0.083 false false false Author 10000028 /api/author/10000028 Zelles Tibor (Idegtudományok) Zelles Tibor true 10000028 true Zelles Tibor true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 122576255 /api/authorship/122576255 Harsing, Laszlo G. [Hársing, László Gábor (Farmakológia), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I) 11 0.083 false false false Author 10000022 /api/author/10000022 Hársing László Gábor (Farmakológia) Hársing László Gábor true 10000022 true Harsing Laszlo G. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 122576256 /api/authorship/122576256 Köles, László ✉ [Köles, László (Farmakológia), szerző] Orálbiológiai Tanszék (SE / FOK); Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I) 12 0.083 false true true Author 10015482 /api/author/10015482 Köles László (Farmakológia) Köles László true 10015482 true Köles László true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 28154643 /api/publicationidentifier/28154643 DOI: 10.3390/biomedicines13010071 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true IDENTICAL 10.3390/biomedicines13010071 https://doi.org/10.3390/biomedicines13010071 false true PublicationIdentifier 28324088 /api/publicationidentifier/28324088 REAL: 214751 SwordSource 36 /api/publicationsource/36 REAL PublicationSourceType 10007 /api/publicationsourcetype/10007 Repozitórium true true true REAL REAL https://real.mtak.hu/@@@ true true 36 true GOLD true IDENTICAL 214751 https://real.mtak.hu/214751 false true PublicationIdentifier 28353412 /api/publicationidentifier/28353412 WoS: 001405955400001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 001405955400001 https://www.webofscience.com/wos/woscc/full-record/001405955400001 false true PublicationIdentifier 28353410 /api/publicationidentifier/28353410 Scopus: 85215784536 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85215784536 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85215784536 false true PublicationIdentifier 28356213 /api/publicationidentifier/28356213 PubMed: 39857655 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 39857655 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=39857655&dopt=Abstract false true Classification 12197 /api/classification/12197 Gyógyszerészet, farmakogenomika, gyógyszerkutatás és tervezés, gyógyszeres kezelés true true SjrRating 11560372 /api/sjrrating/11560372 sjr:Q1 (2025) Scopus - Biochemistry, Genetics and Molecular Biology (miscellaneous) BIOMEDICINES 2227-9059 74 0.24 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 1301 /api/classificationexternal/1301 Scopus - Biochemistry, Genetics and Molecular Biology (miscellaneous) true 1301 true Q1 DIRECT true true Reference 61195361 /api/reference/61195361 1. Fuster, J.M. (2008). Chapter 1—Introduction, in The Prefrontal Cortex, Academic Press. [4th ed.]., DOI: 10.1016/B978-0-12-373644-4.00001-3 1 10.1016/B978-0-12-373644-4.00001-3 false true Reference 61195362 /api/reference/61195362 2. Fuster, J.M. (2008). Chapter 2—Anatomy of the Prefrontal Cortex, in The Prefrontal Cortex, Academic Press. [4th ed.]., DOI: 10.1016/B978-0-12-373644-4.00002-5 2 10.1016/B978-0-12-373644-4.00002-5 false true Reference 61195363 /api/reference/61195363 3. Vyklicky 2014: Structure, function, and pharmacology of NMDA receptor channels., Physiol. Res., 63, p. S191, DOI: 10.33549/physiolres.932678 3 10.33549/physiolres.932678 false true Reference 61195364 /api/reference/61195364 4. Monyer 1992: Heteromeric NMDA receptors: Molecular and functional distinction of subtypes., Science, 256, p. 1217, DOI: 10.1126/science.256.5060.1217 4 10.1126/science.256.5060.1217 false true Reference 61195365 /api/reference/61195365 5. Bayer 2001: Interaction with the NMDA receptor locks CaMKII in an active conformation., Nature, 411, p. 801, DOI: 10.1038/35081080 5 10.1038/35081080 false true Reference 61195366 /api/reference/61195366 6. Traynelis 2010: Glutamate receptor ion channels: Structure, regulation, and function., Pharmacol. Rev., 62, p. 405, DOI: 10.1124/pr.109.002451 6 10.1124/pr.109.002451 false true Reference 61195367 /api/reference/61195367 7. Reisberg 2003: Memantine in moderate-to-severe Alzheimer’s disease., N. Engl. J. Med., 348, p. 1333, DOI: 10.1056/NEJMoa013128 7 10.1056/NEJMoa013128 false true Reference 61195368 /api/reference/61195368 8. Jackson, L., Eldahshan, W., Fagan, S.C., and Ergul, A. (2018). Within the Brain: The Renin Angiotensin System. Int. J. Mol. Sci., 19., DOI: 10.3390/ijms19030876 8 10.3390/ijms19030876 false true Reference 61195369 /api/reference/61195369 9. Swanson 1992: Discovery of a distinct binding site for angiotensin II (3-8), a putative angiotensin IV receptor., Regul. Pept., 40, p. 409, DOI: 10.1016/0167-0115(92)90527-2 9 10.1016/0167-0115(92)90527-2 false true Reference 61195370 /api/reference/61195370 10. Albiston 2001: Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase., J. Biol. Chem., 276, p. 48623, DOI: 10.1074/jbc.C100512200 10 10.1074/jbc.C100512200 false true Reference 61195371 /api/reference/61195371 11. Lew 2003: Angiotensin AT4 ligands are potent, competitive inhibitors of insulin regulated aminopeptidase (IRAP)., J. Neurochem., 86, p. 344, DOI: 10.1046/j.1471-4159.2003.01852.x 11 10.1046/j.1471-4159.2003.01852.x false true Reference 61195372 /api/reference/61195372 12. Wright 1994: Brain angiotensin receptor subtypes in the control of physiological and behavioral responses., Neurosci. Biobehav. Rev., 18, p. 21, DOI: 10.1016/0149-7634(94)90034-5 12 10.1016/0149-7634(94)90034-5 false true Reference 61195373 /api/reference/61195373 13. Wright 1997: Important role for angiotensin III and IV in the brain renin-angiotensin system., Brain Res. Rev., 25, p. 96, DOI: 10.1016/S0165-0173(97)00019-2 13 10.1016/S0165-0173(97)00019-2 false true Reference 61195374 /api/reference/61195374 14. Catt 2000: International union of pharmacology. XXIII. The angiotensin II receptors., Pharmacol. Rev., 52, p. 415 14 false true Reference 61195375 /api/reference/61195375 15. Wright 2015: The development of small molecule angiotensin IV analogs to treat Alzheimer’s and Parkinson’s diseases., Prog. Neurobiol., 125, p. 26, DOI: 10.1016/j.pneurobio.2014.11.004 15 10.1016/j.pneurobio.2014.11.004 false true Reference 61195376 /api/reference/61195376 16. Hanuska, A., Ribiczey, P., Kato, E., Papp, Z.T., Varga, Z.V., Giricz, Z., Toth, Z.E., Konczol, K., Zsembery, A., and Zelles, T. (2024). Potentiation of NMDA Receptors by AT1 Angiotensin Receptor Activation in Layer V Pyramidal Neurons of the Rat Prefrontal Cortex. Int. J. Mol. Sci., 25., DOI: 10.3390/ijms252312644 16 10.3390/ijms252312644 false true Reference 61195377 /api/reference/61195377 17. Wirkner 2002: Interaction between P2Y and NMDA receptors in layer V pyramidal neurons of the rat prefrontal cortex., Neuropharmacology, 42, p. 476, DOI: 10.1016/S0028-3908(01)00199-X 17 10.1016/S0028-3908(01)00199-X false true Reference 61195378 /api/reference/61195378 18. Wirkner 2004: D1 but not D2 dopamine receptors or adrenoceptors mediate dopamine-induced potentiation of N-methyl-d-aspartate currents in the rat prefrontal cortex., Neurosci. Lett., 372, p. 89, DOI: 10.1016/j.neulet.2004.09.015 18 10.1016/j.neulet.2004.09.015 false true Reference 61195379 /api/reference/61195379 19. Wirkner 2007: Modulation of NMDA receptor current in layer V pyramidal neurons of the rat prefrontal cortex by P2Y receptor activation., Cereb. Cortex, 17, p. 621, DOI: 10.1093/cercor/bhk012 19 10.1093/cercor/bhk012 false true Reference 61195380 /api/reference/61195380 20. Oliveira 2008: Blockade of glutamate transporters leads to potentiation of NMDA receptor current in layer V pyramidal neurons of the rat prefrontal cortex via group II metabotropic glutamate receptor activation., Neuropharmacology, 55, p. 447, DOI: 10.1016/j.neuropharm.2008.07.032 20 10.1016/j.neuropharm.2008.07.032 false true Reference 61195381 /api/reference/61195381 21. Kiraly 2015: A new potent analgesic agent with reduced liability to produce morphine tolerance., Brain Res. Bull., 117, p. 32, DOI: 10.1016/j.brainresbull.2015.07.005 21 10.1016/j.brainresbull.2015.07.005 false true Reference 61195382 /api/reference/61195382 22. Koványi, B., Csölle, C., Calovi, S., Hanuska, A., Kató, E., Köles, L., Bhattacharya, A., Haller, J., and Sperlágh, B. (2016). The role of P2X7 receptors in a rodent PCP-induced schizophrenia model. Sci. Rep., 6., DOI: 10.1038/srep36680 22 10.1038/srep36680 false true Reference 61195383 /api/reference/61195383 23. Gage 2012: Whole animal perfusion fixation for rodents., J. Vis. Exp., 65, p. 3564 23 false true Reference 61195384 /api/reference/61195384 24. Harms 2023: Multiplex Immunohistochemistry and Immunofluorescence: A Practical Update for Pathologists., Mod. Pathol., 36, p. 100197, DOI: 10.1016/j.modpat.2023.100197 24 10.1016/j.modpat.2023.100197 false true Reference 61195385 /api/reference/61195385 25. Toth 2007: Simultaneous visualization of multiple antigens with tyramide signal amplification using antibodies from the same species., J. Histochem. Cytochem., 55, p. 545, DOI: 10.1369/jhc.6A7134.2007 25 10.1369/jhc.6A7134.2007 false true Reference 61195386 /api/reference/61195386 26. Koles 2016: Modulation of excitatory neurotransmission by neuronal/glial signalling molecules: Interplay between purinergic and glutamatergic systems., Purinergic Signal., 12, p. 1, DOI: 10.1007/s11302-015-9480-5 26 10.1007/s11302-015-9480-5 false true Reference 61195387 /api/reference/61195387 27. Krugel 2013: Integration of neuronal and glial signalling by pyramidal cells of the rat prefrontal cortex; control of cognitive functions and addictive behaviour by purinergic mechanisms., Neuropsychopharmacol. Hung., 15, p. 206 27 false true Reference 61195388 /api/reference/61195388 28. Hanesworth 1993: Central angiotensin IV binding sites: Distribution and specificity in guinea pig brain., J. Pharmacol. Exp. Ther., 266, p. 1718 28 false true Reference 61195389 /api/reference/61195389 29. Roberts 1995: Autoradiographic identification of brain angiotensin IV binding sites and differential c-Fos expression following intracerebroventricular injection of angiotensin II and IV in rats., Brain Res., 682, p. 13, DOI: 10.1016/0006-8993(95)00289-3 29 10.1016/0006-8993(95)00289-3 false true Reference 61195390 /api/reference/61195390 30. Albrecht 2000: Identification of angiotensin IV binding sites in the mouse brain by a fluorescent binding study., Neuroendocrinology, 72, p. 218, DOI: 10.1159/000054590 30 10.1159/000054590 false true Reference 61195391 /api/reference/61195391 31. Wright 1995: The angiotensin IV system: Functional implications., Front. Neuroendocrinol., 16, p. 23, DOI: 10.1006/frne.1995.1002 31 10.1006/frne.1995.1002 false true Reference 61195392 /api/reference/61195392 32. Moeller 1996: Distribution of AT4 receptors in the Macaca fascicularis brain., Brain Res., 712, p. 307, DOI: 10.1016/0006-8993(95)01482-9 32 10.1016/0006-8993(95)01482-9 false true Reference 61195393 /api/reference/61195393 33. Chai 2000: Distribution of angiotensin IV binding sites (AT4 receptor) in the human forebrain, midbrain and pons as visualised by in vitro receptor autoradiography., J. Chem. Neuroanat., 20, p. 339, DOI: 10.1016/S0891-0618(00)00112-5 33 10.1016/S0891-0618(00)00112-5 false true Reference 61195394 /api/reference/61195394 34. Fernando 2005: Distribution and cellular localization of insulin-regulated aminopeptidase in the rat central nervous system., J. Comp. Neurol., 487, p. 372, DOI: 10.1002/cne.20585 34 10.1002/cne.20585 false true Reference 61195395 /api/reference/61195395 35. Karnik 2015: International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected]., Pharmacol. Rev., 67, p. 754, DOI: 10.1124/pr.114.010454 35 10.1124/pr.114.010454 false true Reference 61195396 /api/reference/61195396 36. Bernstein 2017: Insulin-regulated aminopeptidase immunoreactivity is abundantly present in human hypothalamus and posterior pituitary gland, with reduced expression in paraventricular and suprachiasmatic neurons in chronic schizophrenia., Eur. Arch. Psychiatry Clin. Neurosci., 267, p. 427, DOI: 10.1007/s00406-016-0757-7 36 10.1007/s00406-016-0757-7 false true Reference 61195397 /api/reference/61195397 37. Holownia 2007: The effect of angiotensin II and IV on ERK1/2 and CREB signalling in cultured rat astroglial cells., Naunyn-Schmiedeberg’s Arch. Pharmacol., 376, p. 157, DOI: 10.1007/s00210-007-0192-4 37 10.1007/s00210-007-0192-4 false true Reference 61195398 /api/reference/61195398 38. Yeatman 2011: P3-477: Insulin-regulated aminopeptidase in astrocytes: Role in Alzheimer’s disease?., Alzheimer’s Dement., 7, p. S668, DOI: 10.1016/j.jalz.2011.05.1922 38 10.1016/j.jalz.2011.05.1922 false true Reference 61195399 /api/reference/61195399 39. Wright 2008: Angiotensin receptor subtype mediated physiologies and behaviors: New discoveries and clinical targets., Prog. Neurobiol., 84, p. 157, DOI: 10.1016/j.pneurobio.2007.10.009 39 10.1016/j.pneurobio.2007.10.009 false true Reference 61195400 /api/reference/61195400 40. Koles 2001: Modulation of ionotropic glutamate receptor channels., Neurochem. Res., 26, p. 925, DOI: 10.1023/A:1012380416876 40 10.1023/A:1012380416876 false true Reference 61195401 /api/reference/61195401 41. Park 2015: Angiotensin IV stimulates high atrial stretch-induced ANP secretion via insulin regulated aminopeptidase., Peptides, 63, p. 30, DOI: 10.1016/j.peptides.2014.10.016 41 10.1016/j.peptides.2014.10.016 false true Reference 61195402 /api/reference/61195402 42. Wang 2013: Angiotensin IV upregulates the activity of protein phosphatase 1alpha in Neura-2A cells., Protein Cell, 4, p. 520, DOI: 10.1007/s13238-013-3005-1 42 10.1007/s13238-013-3005-1 false true Reference 61195403 /api/reference/61195403 43. Manzoni 1992: Nitric oxide-induced blockade of NMDA receptors., Neuron, 8, p. 653, DOI: 10.1016/0896-6273(92)90087-T 43 10.1016/0896-6273(92)90087-T false true Reference 61195404 /api/reference/61195404 44. Patel 1998: Angiotensin IV receptor-mediated activation of lung endothelial NOS is associated with vasorelaxation., Am. J. Physiol., 275, p. L1061 44 false true Reference 61195405 /api/reference/61195405 45. Kato 2012: Hepatocyte growth factor overexpression in the nervous system enhances learning and memory performance in mice., J. Neurosci. Res., 90, p. 1743, DOI: 10.1002/jnr.23065 45 10.1002/jnr.23065 false true Reference 61195406 /api/reference/61195406 46. Kawaguchi 1993: Groupings of nonpyramidal and pyramidal cells with specific physiological and morphological characteristics in rat frontal cortex., J. Neurophysiol., 69, p. 416, DOI: 10.1152/jn.1993.69.2.416 46 10.1152/jn.1993.69.2.416 false true Reference 61195407 /api/reference/61195407 47. Yang 1996: Electrophysiological and morphological properties of layers V-VI principal pyramidal cells in rat prefrontal cortex in vitro., J. Neurosci., 16, p. 1904, DOI: 10.1523/JNEUROSCI.16-05-01904.1996 47 10.1523/JNEUROSCI.16-05-01904.1996 false true Reference 61195408 /api/reference/61195408 48. Lee 2001: Potentiation of cholinergic transmission in the rat hippocampus by angiotensin IV and LVV-hemorphin-7., Neuropharmacology, 40, p. 618, DOI: 10.1016/S0028-3908(00)00188-X 48 10.1016/S0028-3908(00)00188-X false true Reference 61195409 /api/reference/61195409 49. Demaegdt 2010: Involvement of the AT1 receptor subtype in the effects of angiotensin IV and LVV-haemorphin 7 on hippocampal neurotransmitter levels and spatial working memory., J. Neurochem., 112, p. 1223, DOI: 10.1111/j.1471-4159.2009.06547.x 49 10.1111/j.1471-4159.2009.06547.x false true Reference 61195410 /api/reference/61195410 50. Olson 2004: Norleucine1-Angiotensin IV alleviates mecamylamine-induced spatial memory deficits., Peptides, 25, p. 233, DOI: 10.1016/j.peptides.2003.12.005 50 10.1016/j.peptides.2003.12.005 false true Reference 61195411 /api/reference/61195411 51. Wilson 2009: The role of the AT4 and cholinergic systems in the Nucleus Basalis Magnocellularis (NBM): Effects on spatial memory., Brain Res., 1272, p. 25, DOI: 10.1016/j.brainres.2009.03.025 51 10.1016/j.brainres.2009.03.025 false true Reference 61195412 /api/reference/61195412 52. Stragier 2004: Metabolism of angiotensin II is required for its in vivo effect on dopamine release in the striatum of the rat., J. Neurochem., 90, p. 1251, DOI: 10.1111/j.1471-4159.2004.02600.x 52 10.1111/j.1471-4159.2004.02600.x false true Reference 61195413 /api/reference/61195413 53. Braszko 2004: Involvement of D1 dopamine receptors in the cognitive effects of angiotensin IV and des-Phe6 angiotensin IV., Peptides, 25, p. 1195, DOI: 10.1016/j.peptides.2004.04.014 53 10.1016/j.peptides.2004.04.014 false true Reference 61195414 /api/reference/61195414 54. Braszko 2006: D2 dopamine receptor blockade prevents cognitive effects of Ang IV and des-Phe6 Ang IV., Physiol. Behav., 88, p. 152, DOI: 10.1016/j.physbeh.2006.03.025 54 10.1016/j.physbeh.2006.03.025 false true Reference 61195415 /api/reference/61195415 55. Braszko 2010: (+)-UH 232, a partial agonist of the D3 dopamine receptors, attenuates cognitive effects of angiotensin IV and des-Phe(6)-angiotensin IV in rats., Eur. Neuropsychopharmacol., 20, p. 218, DOI: 10.1016/j.euroneuro.2009.11.012 55 10.1016/j.euroneuro.2009.11.012 false true Reference 61195416 /api/reference/61195416 56. Braszko 2009: Dopamine D4 receptor antagonist L745,870 abolishes cognitive effects of intracerebroventricular angiotensin IV and des-Phe(6)-Ang IV in rats., Eur. Neuropsychopharmacol., 19, p. 85, DOI: 10.1016/j.euroneuro.2008.08.011 56 10.1016/j.euroneuro.2008.08.011 false true Reference 61195417 /api/reference/61195417 57. Kilic 2021: Angiotensin IV improves spatial memory in streptozotocin-induced diabetic rats by reducing oxidative stress and altering BDNF levels., Acta Neurobiol. Exp., 81, p. 161, DOI: 10.21307/ane-2021-015 57 10.21307/ane-2021-015 false true Reference 61195418 /api/reference/61195418 58. Davis 2006: AT4 receptor activation increases intracellular calcium influx and induces a non-N-methyl-D-aspartate dependent form of long-term potentiation., Neuroscience, 137, p. 1369, DOI: 10.1016/j.neuroscience.2005.10.051 58 10.1016/j.neuroscience.2005.10.051 false true Reference 61195419 /api/reference/61195419 59. Pederson 1998: Attenuation of scopolamine-induced spatial learning impairments by an angiotensin IV analog., Regul. Pept., 74, p. 97, DOI: 10.1016/S0167-0115(98)00028-7 59 10.1016/S0167-0115(98)00028-7 false true Reference 61195420 /api/reference/61195420 60. Wright 1999: Contributions of the brain angiotensin IV-AT4 receptor subtype system to spatial learning., J. Neurosci., 19, p. 3952, DOI: 10.1523/JNEUROSCI.19-10-03952.1999 60 10.1523/JNEUROSCI.19-10-03952.1999 false true Reference 61195421 /api/reference/61195421 61. Lee 2004: Effect of I.C.V. injection of AT4 receptor ligands, NLE1-angiotensin IV and LVV-hemorphin 7, on spatial learning in rats., Neuroscience, 124, p. 341, DOI: 10.1016/j.neuroscience.2003.12.006 61 10.1016/j.neuroscience.2003.12.006 false true Reference 61195422 /api/reference/61195422 62. Albiston 2004: Attenuation of scopolamine-induced learning deficits by LVV-hemorphin-7 in rats in the passive avoidance and water maze paradigms., Behav. Brain Res., 154, p. 239, DOI: 10.1016/j.bbr.2004.02.012 62 10.1016/j.bbr.2004.02.012 false true Reference 61195423 /api/reference/61195423 63. Royea 2020: Brain angiotensin II and angiotensin IV receptors as potential Alzheimer’s disease therapeutic targets., Geroscience, 42, p. 1237, DOI: 10.1007/s11357-020-00231-y 63 10.1007/s11357-020-00231-y false true Reference 61195424 /api/reference/61195424 64. Smolders 2009: Angiotensin IV and LVV-haemorphin 7 enhance spatial working memory in rats: Effects on hippocampal glucose levels and blood flow., Neurobiol. Learn. Mem., 92, p. 19, DOI: 10.1016/j.nlm.2009.02.004 64 10.1016/j.nlm.2009.02.004 false true Reference 61195425 /api/reference/61195425 65. Gard 2008: Cognitive-enhancing effects of angiotensin IV., BMC Neurosci., 9, p. S15, DOI: 10.1186/1471-2202-9-S2-S15 65 10.1186/1471-2202-9-S2-S15 false true Reference 61195426 /api/reference/61195426 66. Andersson 2012: Discovery of inhibitors of insulin-regulated aminopeptidase as cognitive enhancers., Int. J. Hypertens., 2012, p. 789671, DOI: 10.1155/2012/789671 66 10.1155/2012/789671 false true Reference 61195427 /api/reference/61195427 67. Georgiadis, D., Ziotopoulou, A., Kaloumenou, E., Lelis, A., and Papasava, A. (2020). The Discovery of Insulin-Regulated Aminopeptidase (IRAP) Inhibitors: A Literature Review. Front. Pharmacol., 11., DOI: 10.3389/fphar.2020.585838 67 10.3389/fphar.2020.585838 false true Reference 61195428 /api/reference/61195428 68. Stam, F., Bjurling, S., Nylander, E., Hakansson, E.O., Barlow, N., Gising, J., Larhed, M., Odell, L.R., Gronbladh, A., and Hallberg, M. (2024). Inhibition of IRAP Enhances the Expression of Pro-Cognitive Markers Drebrin and MAP2 in Rat Primary Neuronal Cells. Int. J. Mol. Sci., 25., DOI: 10.20944/preprints202407.2523.v1 68 10.20944/preprints202407.2523.v1 false true Reference 61195429 /api/reference/61195429 69. McCoy 2013: Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents., J. Pharmacol. Exp. Ther., 344, p. 141, DOI: 10.1124/jpet.112.199497 69 10.1124/jpet.112.199497 false true Reference 61195430 /api/reference/61195430 70. Lukaszuk 2009: The replacement of His(4) in angiotensin IV by conformationally constrained residues provides highly potent and selective analogues., J. Med. Chem., 52, p. 5612, DOI: 10.1021/jm900651p 70 10.1021/jm900651p false true Reference 61195431 /api/reference/61195431 71. Nikolaou 2013: [3H]IVDE77, a novel radioligand with high affinity and selectivity for the insulin-regulated aminopeptidase., Eur. J. Pharmacol., 702, p. 93, DOI: 10.1016/j.ejphar.2013.01.026 71 10.1016/j.ejphar.2013.01.026 false true Reference 61195432 /api/reference/61195432 72. Axen 2007: Small potent ligands to the insulin-regulated aminopeptidase (IRAP)/AT(4) receptor., J. Pept. Sci., 13, p. 434, DOI: 10.1002/psc.859 72 10.1002/psc.859 false true Reference 61195433 /api/reference/61195433 73. Andersson 2011: Potent macrocyclic inhibitors of insulin-regulated aminopeptidase (IRAP) by olefin ring-closing metathesis., J. Med. Chem., 54, p. 3779, DOI: 10.1021/jm200036n 73 10.1021/jm200036n false true Reference 61195434 /api/reference/61195434 74. Andersson 2010: Disulfide cyclized tripeptide analogues of angiotensin IV as potent and selective inhibitors of insulin-regulated aminopeptidase (IRAP)., J. Med. Chem., 53, p. 8059, DOI: 10.1021/jm100793t 74 10.1021/jm100793t false true Reference 61195435 /api/reference/61195435 75. Barlow 2020: Macrocyclic peptidomimetics as inhibitors of insulin-regulated aminopeptidase (IRAP)., RSC Med. Chem., 11, p. 234, DOI: 10.1039/C9MD00485H 75 10.1039/C9MD00485H false true Reference 61195436 /api/reference/61195436 76. Mpakali 2020: Structural Basis of Inhibition of Insulin-Regulated Aminopeptidase by a Macrocyclic Peptidic Inhibitor., ACS Med. Chem. Lett., 11, p. 1429, DOI: 10.1021/acsmedchemlett.0c00172 76 10.1021/acsmedchemlett.0c00172 false true Reference 61195437 /api/reference/61195437 77. Mountford 2014: Synthesis, structure-activity relationships and brain uptake of a novel series of benzopyran inhibitors of insulin-regulated aminopeptidase., J. Med. Chem., 57, p. 1368, DOI: 10.1021/jm401540f 77 10.1021/jm401540f false true Reference 61195438 /api/reference/61195438 78. Engen 2016: Identification of Drug-Like Inhibitors of Insulin-Regulated Aminopeptidase Through Small-Molecule Screening., Assay Drug Dev. Technol., 14, p. 180, DOI: 10.1089/adt.2016.708 78 10.1089/adt.2016.708 false true Reference 61195439 /api/reference/61195439 79. Borhade 2014: Inhibition of Insulin-Regulated Aminopeptidase (IRAP) by Arylsulfonamides., ChemistryOpen, 3, p. 256, DOI: 10.1002/open.201402027 79 10.1002/open.201402027 false true Reference 61195440 /api/reference/61195440 80. Vanga 2018: Structural Basis of Inhibition of Human Insulin-Regulated Aminopeptidase (IRAP) by Aryl Sulfonamides., ACS Omega, 3, p. 4509, DOI: 10.1021/acsomega.8b00595 80 10.1021/acsomega.8b00595 false true Reference 61195441 /api/reference/61195441 81. Engen 2020: Synthesis, Evaluation and Proposed Binding Pose of Substituted Spiro-Oxindole Dihydroquinazolinones as IRAP Inhibitors., ChemistryOpen, 9, p. 325, DOI: 10.1002/open.201900344 81 10.1002/open.201900344 false true Reference 61195442 /api/reference/61195442 82. Hallberg, M., and Larhed, M. (2020). From Angiotensin IV to Small Peptidemimetics Inhibiting Insulin-Regulated Aminopeptidase. Front. Pharmacol., 11., DOI: 10.3389/fphar.2020.590855 82 10.3389/fphar.2020.590855 false true /api/publication/35663377 Papp Zsolt Tamás et al. Angiotensin IV Receptors in the Rat Prefrontal Cortex: Neuronal Expression and NMDA Inhibition. (2025) BIOMEDICINES 2227-9059 13 1<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10061052"><a href="/gui2/?type=authors&mode=browse&sel=10061052" target="_blank">Papp Zsolt Tamás (<span class="authorship-author-name">Papp Zsolt Tamás</span> <span class="authorAux-mtmt"> Farmakológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Fogorvostudományi Kar">FOK</span>/Orálbiológiai Tanszék; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10069236"><a href="/gui2/?type=authors&mode=browse&sel=10069236" target="_blank">Ribiczey Polett (<span class="authorship-author-name">Szentirmainé Ribiczey Polett</span> <span class="authorAux-mtmt"> Farmakológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Fogorvostudományi Kar">FOK</span>/Orálbiológiai Tanszék; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10015479"><a href="/gui2/?type=authors&mode=browse&sel=10015479" target="_blank">Kató Erzsébet (<span class="authorship-author-name">Kató Erzsébet</span> <span class="authorAux-mtmt"> Farmakológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10001325"><a href="/gui2/?type=authors&mode=browse&sel=10001325" target="_blank">Tóth Zsuzsanna E. (<span class="authorship-author-name">Tóth Zsuzsanna</span> <span class="authorAux-mtmt"> Neuromorfológia, neuroendokrinológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Anatómiai, Szövet- és Fejlődéstani Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10028393"><a href="/gui2/?type=authors&mode=browse&sel=10028393" target="_blank">Varga Zoltán V. (<span class="authorship-author-name">Varga Zoltán</span> <span class="authorAux-mtmt"> kardiovaszkuláris kutatás</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10026898"><a href="/gui2/?type=authors&mode=browse&sel=10026898" target="_blank">Giricz Zoltán (<span class="authorship-author-name">Giricz Zoltán</span> <span class="authorAux-mtmt"> Biokémia, Farmakológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10039322"><a href="/gui2/?type=authors&mode=browse&sel=10039322" target="_blank">Hanuska Adrienn (<span class="authorship-author-name">Hanuska Adrienn</span> <span class="authorAux-mtmt"> farmakológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Fogorvostudományi Kar">FOK</span>/Orálbiológiai Tanszék; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10015484"><a href="/gui2/?type=authors&mode=browse&sel=10015484" target="_blank">Al-Khrasani Mahmoud (<span class="authorship-author-name">Al-Khrasani Mahmoud</span> <span class="authorAux-mtmt"> Farmakológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10015697"><a href="/gui2/?type=authors&mode=browse&sel=10015697" target="_blank">Zsembery Ákos (<span class="authorship-author-name">Zsembery Ákos</span> <span class="authorAux-mtmt"> Élettan</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Fogorvostudományi Kar">FOK</span>/Orálbiológiai Tanszék</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10000028"><a href="/gui2/?type=authors&mode=browse&sel=10000028" target="_blank">Zelles Tibor (<span class="authorship-author-name">Zelles Tibor</span> <span class="authorAux-mtmt"> Idegtudományok</span>) </a> </span> <span class="author-affil"><span title="HUN-REN Kísérleti Orvostudományi Kutatóintézet">HRN KOKI</span>/Molekuláris Farmakológia Kutatócsoport; <span title="Semmelweis Egyetem">SE</span>/<span title="Fogorvostudományi Kar">FOK</span>/Orálbiológiai Tanszék; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10000022"><a href="/gui2/?type=authors&mode=browse&sel=10000022" target="_blank">Harsing Laszlo G. (<span class="authorship-author-name">Hársing László Gábor</span> <span class="authorAux-mtmt"> Farmakológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10015482"><a href="/gui2/?type=authors&mode=browse&sel=10015482" target="_blank">Köles László ✉ (<span class="authorship-author-name">Köles László</span> <span class="authorAux-mtmt"> Farmakológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Fogorvostudományi Kar">FOK</span>/Orálbiológiai Tanszék; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;35663377" target="_blank">Angiotensin IV Receptors in the Rat Prefrontal Cortex: Neuronal Expression and NMDA Inhibition</a></div> <div> <span class="journal-title">BIOMEDICINES</span> <span class="journal-issn">( <a target="_blank" href="https://portal.issn.org/resource/ISSN/2227-9059">2227-9059</a>)</span>: <span class="journal-volume">13</span> <span class="journal-issue">1</span> <span class="page"> Paper 71. 19 p. </span> <span class="year">(2025)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="10.3390/biomedicines13010071" target="_blank" href="https://doi.org/10.3390/biomedicines13010071"> DOI </a> </span> <span class="id identifier oa_GOLD" title=" Gold "> <a style="color:blue" title="214751" target="_blank" href="https://real.mtak.hu/214751"> REAL </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="001405955400001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/001405955400001"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85215784536" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85215784536"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="39857655" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=39857655&dopt=Abstract"> PubMed </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Biochemistry, Genetics and Molecular Biology (miscellaneous)&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Medicine (miscellaneous)&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 5</span> | Független: 5 | Függő: 0 | Nem jelölt: 0 | WoS jelölt: 4 | Scopus jelölt:&nbsp;4 | WoS/Scopus jelölt:&nbsp;4 | DOI jelölt:&nbsp;4 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;35663377&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 11 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 35663377</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Szakcikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">kézi felvitel</span> </div> <div class="funder"> (OTKA-K128875), (NKFI K 146086), (TKP2021-EGA-23) Támogató: Innovációs és Technológiai Minisztérium, (TKP2021-EGA-25) </div> <div class="lastModified">Utolsó módosítás: 2026.04.29. 08:04 Sághi-Keszthelyi Anna (SE_KK_Admin5_SKA, admin) </div> <div class="lockedBy">Központi kezelésű 2026.05.20. 09:50 Lévayné Deseő Katalin (MTMT Központi admin) </div> <pre class="comment" style="margin-top: 0; margin-bottom: 0;"><u>Megjegyzés</u>: Funding Agency and Grant Number: Ministry of Innovation and Technology of Hungary [TKP2021-EGA-23, TKP2021-EGA-25]; Ministry of Innovation and Technology of Hungary from the National Research, Development, and Innovation Fund [OTKA-K128875, NKFI K 146086]; National Research, Development, and Innovation Office of Hungary Funding text: This work was supported by the Ministry of Innova...</pre> </div></div>